GlassScriptPhysician profile
Noga Askenazi
NPI 1972518702
$11,928.88
in general payments reported to CMS, 2019-2025
39 companies · $1,961 in 2025
The $1,961 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,097 · 2020: $1,303 · 2021: $1,672 · 2022: $1,333 · 2023: $1,609 · 2024: $1,955 · 2025: $1,961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,234 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,233.79 |
| Education | $291.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,181.99 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Genzyme Corporation | $1,530.56 | 2019-2025 | |
| Csl Behring | $1,013.03 | 2019-2025 | Hizentra, Kcentra, Haegarda |
| Glaxosmithkline, LLC. | $936.74 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $862.57 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $681.50 | 2019-2025 | Cuvitru, Takhzyro, Hyqvia |
| Pfizer INC. | $450.48 | 2019-2025 | |
| Genentech USA, INC. | $377.73 | 2019-2025 | Xolair |
| Blueprint Medicines Corporation | $357.52 | 2023-2025 | Ayvakit |
| Octapharma USA, INC. | $285.49 | 2019-2024 | Cutaquig |
| Shire North American Group INC | $267.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $264.47 | 2019-2021 | |
| Grifols USA, LLC | $264.35 | 2019-2025 | Xembify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.98 | 2019-2023 | Spiriva Respimat |
| Hospira, INC. | $217.71 | 2022-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noga Askenazi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.